Expression of hla-dr in cytotoxic t lymphocytes
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| Texto Completo: | http://hdl.handle.net/10362/124267 |
Resumo: | Funding Information: Funding: This work was supported by Terry Fox Research Grant 2019 from Liga Portuguesa Contra o Cancro; Clinical Research Prize 2018 from Consortium Tagus Tank; Fundação para a Ciência e Tecnologia (PD/BD/114023/2015 for DPS and SFRH/BD/148422/2019 for RS) and iNOVA4Health (UIDB/04462/2020, DAI/2019/46). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
| id |
RCAP_5d08e8ea83db439953951cb467db2c8f |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/124267 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository_id_str |
https://opendoar.ac.uk/repository/7160 |
| spelling |
Expression of hla-dr in cytotoxic t lymphocytesA validated predictive biomarker and a potential therapeutic strategy in breast cancer3D co-culturesBiomarkerBreast cancerCytotoxic T lymphocytesHLA-DRImmune-modulationNeoadjuvant chemotherapyOncologyCancer ResearchSDG 3 - Good Health and Well-beingFunding Information: Funding: This work was supported by Terry Fox Research Grant 2019 from Liga Portuguesa Contra o Cancro; Clinical Research Prize 2018 from Consortium Tagus Tank; Fundação para a Ciência e Tecnologia (PD/BD/114023/2015 for DPS and SFRH/BD/148422/2019 for RS) and iNOVA4Health (UIDB/04462/2020, DAI/2019/46). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.Neoadjuvant chemotherapy (NACT) is common in breast cancer (BC) treatment, though more than half of the patients lack an effective response. Therefore, new predictive biomarkers and alternative therapies are crucial. Previously, we proposed HLA-DR-expressing cytotoxic T lymphocytes (CTLs) as a potential biomarker of the response to NACT. To validate this observation and further investigate these cells, 202 BC patients were enrolled. Flow cytometry analyses were performed in 61 biopsies and 41 blood samples pre-NACT and 100 non-NACT tumor samples. All the patients were followed up for 34 months. Blood-isolated immune cells were cultured with BC cell lines in a 3D system. We confirmed that HLA-DR level in CTLs is a highly sensitive, specific, and independent biomarker to predict response to NACT and developed a predictive probability model. This biomarker was also associated with progression-free survival, regardless of the treatment. The clinical observations are substantiated by the anti-tumor properties of HLA-DR-expressing CTLs. Intriguingly, HLA-DR level in CTLs can be modulated ex vivo, boosting their capacity to kill tumor cells synergistically with doxorubicin. Thus, HLA-DR expression in CTLs is a validated tool to select patients that will actually benefit from NACT, and its stimulation might be a novel therapeutic approach for BC.iNOVA4Health - pólo NMSCentro de Estudos de Doenças Crónicas (CEDOC)NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Comprehensive Health Research Centre (CHRC) - pólo NMSRUNSaraiva, Diana P.Azeredo-Lopes, SofiaAntunes, AnaSalvador, RuteBorralho, PaulaAssis, BeatrizPereira, Isabel L.Seabra, ZitaNegreiros, IdaJacinto, AntónioBraga, SofiaCabral, M. Guadalupe2021-09-09T00:27:36Z2021-08-012021-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/124267eng2072-6694PURE: 33427169https://doi.org/10.3390/cancers13153841info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T17:55:58Zoai:run.unl.pt:10362/124267Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:26:55.077775Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
| dc.title.none.fl_str_mv |
Expression of hla-dr in cytotoxic t lymphocytes A validated predictive biomarker and a potential therapeutic strategy in breast cancer |
| title |
Expression of hla-dr in cytotoxic t lymphocytes |
| spellingShingle |
Expression of hla-dr in cytotoxic t lymphocytes Saraiva, Diana P. 3D co-cultures Biomarker Breast cancer Cytotoxic T lymphocytes HLA-DR Immune-modulation Neoadjuvant chemotherapy Oncology Cancer Research SDG 3 - Good Health and Well-being |
| title_short |
Expression of hla-dr in cytotoxic t lymphocytes |
| title_full |
Expression of hla-dr in cytotoxic t lymphocytes |
| title_fullStr |
Expression of hla-dr in cytotoxic t lymphocytes |
| title_full_unstemmed |
Expression of hla-dr in cytotoxic t lymphocytes |
| title_sort |
Expression of hla-dr in cytotoxic t lymphocytes |
| author |
Saraiva, Diana P. |
| author_facet |
Saraiva, Diana P. Azeredo-Lopes, Sofia Antunes, Ana Salvador, Rute Borralho, Paula Assis, Beatriz Pereira, Isabel L. Seabra, Zita Negreiros, Ida Jacinto, António Braga, Sofia Cabral, M. Guadalupe |
| author_role |
author |
| author2 |
Azeredo-Lopes, Sofia Antunes, Ana Salvador, Rute Borralho, Paula Assis, Beatriz Pereira, Isabel L. Seabra, Zita Negreiros, Ida Jacinto, António Braga, Sofia Cabral, M. Guadalupe |
| author2_role |
author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
iNOVA4Health - pólo NMS Centro de Estudos de Doenças Crónicas (CEDOC) NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Comprehensive Health Research Centre (CHRC) - pólo NMS RUN |
| dc.contributor.author.fl_str_mv |
Saraiva, Diana P. Azeredo-Lopes, Sofia Antunes, Ana Salvador, Rute Borralho, Paula Assis, Beatriz Pereira, Isabel L. Seabra, Zita Negreiros, Ida Jacinto, António Braga, Sofia Cabral, M. Guadalupe |
| dc.subject.por.fl_str_mv |
3D co-cultures Biomarker Breast cancer Cytotoxic T lymphocytes HLA-DR Immune-modulation Neoadjuvant chemotherapy Oncology Cancer Research SDG 3 - Good Health and Well-being |
| topic |
3D co-cultures Biomarker Breast cancer Cytotoxic T lymphocytes HLA-DR Immune-modulation Neoadjuvant chemotherapy Oncology Cancer Research SDG 3 - Good Health and Well-being |
| description |
Funding Information: Funding: This work was supported by Terry Fox Research Grant 2019 from Liga Portuguesa Contra o Cancro; Clinical Research Prize 2018 from Consortium Tagus Tank; Fundação para a Ciência e Tecnologia (PD/BD/114023/2015 for DPS and SFRH/BD/148422/2019 for RS) and iNOVA4Health (UIDB/04462/2020, DAI/2019/46). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-09-09T00:27:36Z 2021-08-01 2021-08-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/124267 |
| url |
http://hdl.handle.net/10362/124267 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
2072-6694 PURE: 33427169 https://doi.org/10.3390/cancers13153841 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
| instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| repository.mail.fl_str_mv |
info@rcaap.pt |
| _version_ |
1833596704125878272 |